Table 3.
Ongoing phase III trials in patients with advanced HCC.
| Drugs | Phase | Setting | Endpoint | ClinicalTrials.gov Identifier |
|---|---|---|---|---|
| SBRT followed by sintilimab vs. SBRT | II/III | Palliative—1st line | Primary: 24-week PFS rate Secondary: PFS; OS; ORR; DCR; DOR |
NCT04167293 |
| Lenvatinib + pembrolizumab +TACE vs. TACE | III | Palliative—1st line | Primary: PFS; OS Secondary: ORR; DCR; DOR; TTP; AEs |
NCT04246177 |
| Arm A: TACE + durvalumab; Arm B: TACE + durvalumab + bevacizumab; Arm C: TACE |
III | Palliative—1st line | Primary: PFS (Arm B vs. Arm C) Secondary: PFS (Arm A vs. Arm C); OS |
NCT03778957 |
| Nivolumab + Ipilimumab vs. sorafenib or lenvatinib | III | Palliative—1st line | Primary: OS Secondary: ORR; DOR; TTSD |
NCT04039607 |
| Finotonlimab (anti PD1) + SCT510 (bavacizumab) vs. Sorafenib | II/III | Palliative—1st line | Primary: OS Secondary: ORR; PFS |
NCT04560894 |
| Toripalimab + Lenvatinib vs. Lenvatinib | III | Palliative—1st line | Primary: OS, PFS Secondary: ORR; DOR; TTP |
NCT04523493 |
| Nofazinlimab (CS1003) + Lenvatinib vs. Lenvatinib | III | Palliative—1st line | Primary: OS, PFS | NCT04194775 |
| Atezolizumab + Lenvatinib or Sorafenib vs. Lenvatinib or Sorafenib | III | Palliative—2nd line | Primary: OS Secondary: ORR; PFS; DOR; TTP |
NCT04770896 |